STOCK TITAN

BioCardia Inc. - BCDA STOCK NEWS

Welcome to our dedicated news page for BioCardia (Ticker: BCDA), a resource for investors and traders seeking the latest updates and insights on BioCardia.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioCardia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioCardia's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
conferences
BioCardia Inc.

Nasdaq:BCDA

BCDA Rankings

BCDA Stock Data

10.86M
14.61M
36.24%
8.04%
0.38%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Carlos

About BCDA

we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.